Tiazofurine

Drug Profile

Tiazofurine

Alternative Names: CI 909; CPD 5825; ICN 5825; NSC 286193; Riboxamide; Tiazofurin; Tiazole

Latest Information Update: 16 Jun 2003

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Amides; Cytostatics; Ribonucleosides; Small molecules; Thiazoles
  • Mechanism of Action Immunomodulators; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloid leukaemia

Highest Development Phases

  • Suspended Multiple myeloma; Myeloid leukaemia; Ovarian cancer

Most Recent Events

  • 16 Jun 2003 Suspended - Phase-II for Ovarian cancer in Russia (IV)
  • 16 Jun 2003 Suspended - Phase-III for Myeloid leukaemia in USA (IV)
  • 16 Jun 2003 Suspended - Phase-I for Multiple myeloma in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top